IL313219A - M4 muscarinic acetylcholine receptor antagonists - Google Patents
M4 muscarinic acetylcholine receptor antagonistsInfo
- Publication number
- IL313219A IL313219A IL313219A IL31321924A IL313219A IL 313219 A IL313219 A IL 313219A IL 313219 A IL313219 A IL 313219A IL 31321924 A IL31321924 A IL 31321924A IL 313219 A IL313219 A IL 313219A
- Authority
- IL
- Israel
- Prior art keywords
- halogen
- antagonists
- hydrogen
- independently selected
- membered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284750P | 2021-12-01 | 2021-12-01 | |
| PCT/US2022/051493 WO2023102100A1 (en) | 2021-12-01 | 2022-12-01 | Antagonists of the muscarinic acetylcholine receptor m4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL313219A true IL313219A (en) | 2024-07-01 |
Family
ID=84943708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313219A IL313219A (en) | 2021-12-01 | 2022-12-01 | M4 muscarinic acetylcholine receptor antagonists |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250145595A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4441046A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024543973A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240112343A (cg-RX-API-DMAC10.html) |
| CN (2) | CN116669737A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022400780A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3241298A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL313219A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024006718A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023102100A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3651762B1 (en) | 2017-07-12 | 2024-07-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| JP7270989B2 (ja) | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| US12319701B2 (en) | 2019-10-04 | 2025-06-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| JP2024500880A (ja) * | 2020-12-22 | 2024-01-10 | ヴァンダービルト ユニヴァーシティ | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| WO2022261427A1 (en) | 2021-06-11 | 2022-12-15 | Vanderbilt University | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102474326B1 (ko) * | 2016-06-22 | 2022-12-05 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제 |
| AU2018313802A1 (en) * | 2017-08-08 | 2020-02-20 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| JP7270989B2 (ja) * | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| WO2021119254A1 (en) * | 2019-12-10 | 2021-06-17 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| US20230183219A1 (en) * | 2020-04-24 | 2023-06-15 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| CA3180717A1 (en) * | 2020-04-24 | 2021-10-28 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
-
2021
- 2021-12-22 CN CN202180087480.8A patent/CN116669737A/zh active Pending
-
2022
- 2022-12-01 CN CN202280088712.6A patent/CN118541365A/zh active Pending
- 2022-12-01 IL IL313219A patent/IL313219A/en unknown
- 2022-12-01 MX MX2024006718A patent/MX2024006718A/es unknown
- 2022-12-01 US US18/715,048 patent/US20250145595A1/en active Pending
- 2022-12-01 JP JP2024532491A patent/JP2024543973A/ja active Pending
- 2022-12-01 WO PCT/US2022/051493 patent/WO2023102100A1/en not_active Ceased
- 2022-12-01 EP EP22843543.4A patent/EP4441046A1/en active Pending
- 2022-12-01 CA CA3241298A patent/CA3241298A1/en active Pending
- 2022-12-01 AU AU2022400780A patent/AU2022400780A1/en active Pending
- 2022-12-01 KR KR1020247021498A patent/KR20240112343A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240112343A (ko) | 2024-07-18 |
| AU2022400780A1 (en) | 2024-06-20 |
| CA3241298A1 (en) | 2023-06-08 |
| US20250145595A1 (en) | 2025-05-08 |
| CN118541365A (zh) | 2024-08-23 |
| CN116669737A (zh) | 2023-08-29 |
| WO2023102100A1 (en) | 2023-06-08 |
| JP2024543973A (ja) | 2024-11-26 |
| MX2024006718A (es) | 2024-08-09 |
| EP4441046A1 (en) | 2024-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3053484T3 (en) | Cyclopropyl dihydroquinoline sulfonamide compounds | |
| ES2598118T3 (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de PI3Ks | |
| ES2566205T3 (es) | Inhibidores de quinasa TYK2 | |
| JP2025179137A (ja) | シクロブチルジヒドロキノリンスルホンアミド化合物 | |
| EP4165032A1 (en) | Heteroalkyl dihydroquinoline sulfonamide compounds | |
| JP5815411B2 (ja) | ピリミジンジアミンキナーゼ阻害剤 | |
| EA017806B1 (ru) | Антимикробные соединения, их синтез и применение для лечения инфекций у млекопитающих | |
| HRP20220177T1 (hr) | Heteroaril supstituirani beta-hidroksietilamini za upotrebu u liječenju hiperglikemije | |
| JP6903663B2 (ja) | アルキルジヒドロキノリンスルホンアミド化合物 | |
| AU2014231722B2 (en) | Salts, co-crystals, and polymorphs of an anxiolytic compound | |
| CR20190147A (es) | DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO | |
| AU2016248886A1 (en) | Pyridopyrimidinones and their use as NMDA receptor modulators | |
| JP2018537505A (ja) | アルキニルジヒドロキノリンスルホンアミド化合物 | |
| CA2613155A1 (en) | Substituted cyclobutane,its preparation process and its medical use | |
| CA3187516A1 (en) | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza | |
| AU2016420300B2 (en) | Novel salt of (R)-(1-methylpyrrolidin-3-yl)methyl(3'-chloro-4'-fluoro-[1,1'-biphenyl]-2-yl)carbamate and crystal form thereof | |
| WO2007075297A2 (en) | Muscarinic agonists and methods of use thereof | |
| WO2025043079A1 (en) | Compounds, compositions, and methods | |
| KR100647824B1 (ko) | 다약제 내성 극복성을 갖는 옥사트리아자치리센 화합물 및이의 제조방법 | |
| WO2022165045A1 (en) | Reactivation of embryonic and fetal hemoglobin | |
| CN121270500A (zh) | 含一氧化氮供体的黄酮类衍生物 | |
| WO2020146878A1 (en) | Salt and crystalline forms of rapastinel | |
| EA050562B1 (ru) | Циклобутилдигидрохинолинсульфонамидные соединения | |
| TH78309A (th) | สารยับยั้งมายคอแบคทีเรียชนิดใหม่ | |
| TH65569B (th) | สารยับยั้งมายคอแบคทีเรียชนิดใหม่ |